BHVN Biohaven Pharmaceutical Holding Company Ltd.

54.5
-1.47  -3%
Previous Close 55.97
Open 56
Price To Book 23.9
Market Cap 2,847,080,491
Shares 52,240,009
Volume 731,764
Short Ratio 8.84
Av. Daily Volume 749,084
Stock charts supplied by TradingView

NewsSee all news

  1. Biohaven's Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General

    NEW HAVEN, Conn., Jan. 22, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company with multiple late-stage neuroscience

  2. Kleo Pharmaceuticals to Present at Biotech Showcase 2020

    NEW HAVEN, Conn., Dec. 18, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  3. Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine

    NEW HAVEN, Conn., Dec. 17, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3

  4. Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study

    NEW HAVEN, Conn., Dec. 6, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting

  5. Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office

    NEW HAVEN, Conn., Dec. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 enrolment to be completed by end of 2019.
TRORILUZOLE
Obsessive compulsive disorder (OCD)
CRL issued July 19, 2019.
Nurtec (riluzole) (BHV-0223)
Amyotrophic lateral sclerosis (ALS)
Phase 3 top-line data due early-1Q 2020.
Rimegepant
Migraine - preventative
NDA filing submitted 2Q 2019.
Rimegepant
Acute treatment of migraine
Phase 2/3 passed interim futility analysis December 6, 2019.
TRORILUZOLE
Alzheimer’s disease
Phase 2/3 data due early-1Q 2020.
TRORILUZOLE
Generalized anxiety disorder (GAD)
Phase 3 commencement of enrolment announced July 31, 2019.
Verdiperstat
Multiple system atrophy (MSA)
Phase 2/3 top-line data met primary endpoint - December 17, 2019.
Vazegepant
Acute treatment of migraine
Phase 3 enrolment to be completed 1Q 2020.
TRORILUZOLE
Spinocerebellar Ataxia (SCA)
Phase 2 commencement of enrolment announced July 1, 2019.
Rimegepant
Refractory trigeminal neuralgia

Latest News

  1. Biohaven's Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General

    NEW HAVEN, Conn., Jan. 22, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a biopharmaceutical company with multiple late-stage neuroscience

  2. Kleo Pharmaceuticals to Present at Biotech Showcase 2020

    NEW HAVEN, Conn., Dec. 18, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  3. Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine

    NEW HAVEN, Conn., Dec. 17, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3

  4. Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study

    NEW HAVEN, Conn., Dec. 6, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting

  5. Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office

    NEW HAVEN, Conn., Dec. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of

  6. Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference

    NEW HAVEN, Conn., Dec. 2, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  7. Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting

    NEW HAVEN, Conn., Nov. 6, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of

  8. Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole

    NEW HAVEN, Conn., Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting

  9. Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

    NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a clinical-stage biopharmaceutical company provided an update regarding the appointment of Thomas J. Lynch, Jr., MD,

  10. Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments

    NEW HAVEN, Conn., Nov. 1, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage

  11. Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)

    NEW HAVEN, Conn., Sept. 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of

  12. Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine

    NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases,

  13. Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session

    NEW HAVEN, Conn., Sept. 9, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced today that it presented expanded data and post-hoc analyses from its long term clinical study